|
FDA announced on Tuesday that it has approved another new obesity drug — the second new weight-loss drug approved in less than a month. Marketed as Qsymia, the once-daily pill combines the appetite suppressant phentermine with an extended-release formulation of the anticonvulsant topiramate.Qsymia, previously called Qnexa, is indicated for adults with a BMI of 30 or higher, or for those with a BMI...
|
|
|
The U.S. Food and Drug Administration (FDA) has approved a new weight- loss drug manufactured by the pharmaceutical company Vivus.According to the BBC, the FDA approved the use of Qsymia for patients who are overweight or obese and have at least one other weight-related condition.The approval comes after the FDA gave another anti-obesity drug, Belviq, the green signal last month.The FDA said that two...
|
|
|
drugs react with each other and can cause side effects, sometimes serious and sometimes, fatal. Here are some common cases.Sildenafil and tadalafil used by men with erectile dysfunction interact with other drugs such as nitrates, amyl nitrite, glyceryl trinitrate, isosorbide, all commonly used in the treatment of angina.Concurrent use can result in a severe dip in BP that may turn fatal. n Most antacids...
|
|
|
regulators have approved a new weight-loss drug that many doctors consider the most effective therapy in a new generation of anti-obesity pills designed to help patients safely shed pounds....
|
|
|
second new weight-management drug in 13 years has been approved by US regulators for use in people who are obese or overweight and have certain medical conditions.) approval just a month after another anti-obesity drug, called Belviq, was given a thumbs up.Qsymia has been approved for use in obese adults with a body mass index (BMI) of 30 or greater or for overweight adults with a BMI of 27 or greater...
|
|
|
Drug Reduces Chances of Dangerous Complications in Bone Marrow Transplant PatientsDisclaimer...
|
|
